No. HT942526NFRPIIRA · Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Investigator-Initiated Research Award
- Award range
- Not specified
- Expected awards
- ~7
- Application deadline
- Sep 22, 2026 20 days left
- Posted
- Jun 25, 2026
- Last verified
- Yesterday
At a glance
AI summaryThis program funds high-impact neurofibromatosis research that can advance understanding, diagnosis, treatment, or patient care, and it does not allow clinical trials. Eligible applicants include U.S. Department of War organizations as well as foreign or domestic, for-profit or nonprofit, and public or private organizations; the principal investigator must be at least an assistant professor or equivalent and commit at least 10% effort. The award has two funding levels: Level 1 awards are capped at $840,000 in total costs and Level 2 awards are capped at $920,000, with approximately five Level 1 awards and two Level 2 awards expected. The maximum project period is 3 years, cost sharing is not required, and awards are made to organizations rather than individuals. There are no geographic restrictions stated, but projects using the Open Science Initiative or a qualified collaborator may be eligible for the higher funding level.
AI-generated summary — verify against the announcement
What it funds
Official description from grants.gov
Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Investigator-Initiated Research Award (IIRA) supports high-impact research that addresses a critical need and has the potential to make important contributions to the field of neurofibromatosis disorders or advance patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project. Distinctive Features: This award mechanism offers two funding levels based on participation in two optional features: • Open Science Initiative: Catalyzes research for neurofibromatosis through early access to data and data sharing within the neurofibromatosis community. • Optional Qualified Collaborator: Encourages collaborative research between basic scientists and clinical researchers, and between academic and biotechnology scientists. The funding levels are defined as follows: • Level 1: Applications without an optional feature. • Level 2: Applications including one of the optional features.
Who can apply
- Unrestricted
Program history
USASpending.govAssistance listing 12.420 · Military Medical Research and Development
Real awards this federal program has made — the whole assistance listing (12.420), not just this notice.
| Fiscal year | Awards | Median award | Middle half |
|---|---|---|---|
| FY 2026 (so far) | 374 | $934,195 | $559,998 – $1,477,811 |
| FY 2025 | 967 | $796,174 | $416,995 – $1,480,602 |
| FY 2024 | 1,097 | — | — |
| FY 2023 | 1,115 | — | — |
| FY 2022 | 1,186 | — | — |
| FY 2021 | 1,023 | — | — |
Dollar figures are based on the 1,000 most recent awards we store, not all 5,762 — award counts are complete.
- THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER $19,100,256 · FY 2025
- H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. $18,696,738 · FY 2025
- UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE $10,606,583 · FY 2025
- SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH $10,500,000 · FY 2026
- UNIVERSITY OF VERMONT & STATE AGRICULTURAL COLLEGE $8,491,997 · FY 2025
Source: USASpending.gov · refreshed Aug 25, 2026